Richard Epstein on Regulation
2010-09-20 · 67 min · episode 229 · 18 entities
Asserted relationships
-
0.63
evidence rules-v4
Richard Epstein on Regulation
-
0.55
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.55
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
-
0.40
evidence rules-v4
Feed category: Society & Culture
-
0.40
evidence rules-v4
Feed category: Science
-
0.40
evidence rules-v4
Feed category: Philosophy
-
0.40
evidence rules-v4
Feed category: Education
-
0.40
evidence rules-v4
Feed category: Courses
-
0.40
evidence rules-v4
Feed category: Social Sciences
Entities found in this episode
concepts 12
-
0.50
evidence rules-v4
Feed category: Society & Culture
-
0.50
evidence rules-v4
Feed category: Science
-
0.50
evidence rules-v4
Feed category: Philosophy
-
0.50
evidence rules-v4
Feed category: Education
-
0.50
evidence rules-v4
Feed category: Courses
-
0.50
evidence rules-v4
Feed category: Social Sciences
-
0.40
evidence rules-v4
Feed category: Society & Culture
-
0.40
evidence rules-v4
Feed category: Science
-
0.40
evidence rules-v4
Feed category: Philosophy
-
0.40
evidence rules-v4
Feed category: Education
-
0.40
evidence rules-v4
Feed category: Courses
-
0.40
evidence rules-v4
Feed category: Social Sciences
persons 5
-
0.70
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.70
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
-
0.66
evidence rules-v4
Richard Epstein on Regulation
-
0.55
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.55
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
podcasts 1
-
0.63
evidence rules-v4
Richard Epstein on Regulation
Episode description as stored
Richard Epstein of New York University and Stanford University's Hoover Institution talks with EconTalk host Russ Roberts about the current state of the economy, particularly the regulatory climate. Epstein argues the current level of regulation is producing unusually high costs. He digs more deeply into the pharmaceutical industry and discusses various regulations and alternative ways to encourage drug safety and innovation.